ATHENA study evaluating Rubraca® (rucaparib) monotherapy versus placebo (ATHENA-MONO) in first-line ovarian cancer maintenance treatment successfully achieved the primary endpoint of improved PFS in both populations in the primary efficacy analyses: HRD-positive and all patients randomized (ITT)
Median PFS of 20.2 months for Rubraca vs 9.2 months for placebo in ITT population
Late-breaker data to be presented in oral session at 2022 ASCO Annual Meeting on Monday, June 6
Two additional top-line Phase 3 data read-outs for Rubraca expected in next 12 months with potential to address ovarian and prostate cancer patient populations
Initial Phase 1 clinical data for targeted radiotherapy candidate FAP-2286 to be presented in oral presentation at SNMMI 2022 Annual Meeting on Tuesday, June 14
Initiation of Phase 2 expansion cohorts in multiple tumor types anticipated in Q4 2022
$34.2M in Rubraca global net product revenues for Q1 2022, down 10% vs Q1 2021 and down 5% vs Q4 2021
Continued impact of COVID-19 on ovarian cancer diagnoses and treatments
Reduction in R&D expense of $10.6M or 20% compared to Q1 2021
$122.2M in cash and cash equivalents and $18.6M in available funding under the ATHENA financing at March 31, 2022
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.